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ABSTRACT
Introduction: Clinical and animal studies of chimeric monoclonal antibody G250 (moAb cG250) for the
targeting of clear-cell renal cell carcinoma (RCC), to date, have been with the intact IgG form. To de-
termine whether F(ab9)2 fragments are more suited for radioimmunotherapy (RIT) than intact IgG, biodis-
tribution experiments in nude mice were performed, and a pilot study in RCC patients was carried out.
In these studies, the biodistribution, pharmacokinetics, and tumor-targeting characteristics of 131I-cG250-
F(ab9)2 fragments were determined. Methods: The biodistribution of intact IgG and F(ab9)2 fragments
(moAb cG250) was directly compared in mice with subcutaneous (s.c.) RCC xenografts that were coin-
jected with 125I-cG250-IgG and 131I-cG250-F(ab9)2 fragments. Groups of 5 mice were dissected at 1, 2,
3, 5, and 7 days postinjection (p.i.). The activity in tumor and normal tissues was expressed as the per-
centage of the injected dose per gram (%ID/g). Five (5) patients with evidence of primary RCC on com-
puted tomography (CT) and scheduled for nephrectomy received a diagnostic infusion of 150 MBq 131I-
cG250-F(ab9)2. At various time points after injection of the antibody preparation (5 minutes, 3 hours, and
1, 2, 3, and 4 days), whole-body gamma camera images were acquired. After surgery, histology was de-
termined and immunohistochemistry was performed. The scintigraphic images were analyzed visually and
quantitatively. Radioactivity in whole-body, normal tissues and primary RCC was calculated and ex-
pressed as %ID. Results: In mice, 131I-cG250-F(ab9)2 fragments cleared faster from the blood and other
tissues, and absolute uptake in tumor (3.4 6 0.9 %ID/g at 24 hours p.i.) and normal tissues was consid-
erably lower compared to intact 125I-cG250. However, the tissue-to-blood ratios for both antibody prepa-
rations were similar for most tissues and at most time points. The results in patients corresponded with
the results of the studies in mice. The 131I-cG250-F(ab9)2 fragments cleared rapidly from the blood and
body. The half-life of the distribution and elimination phase (t 1/2 a and t 1/2 b) in blood of RCC patients
were 4.8 6 0.9 hours and 29.0 6 3.3 hours, respectively. At 4 days p.i., whole-body activity was 20%ID.
Faint visualization of tumor was observed in only 2 of 5 patients. Conclusions: In mice, the tissue-to-
blood ratios were similar for intact IgG and the 131I-cG250-F(ab9)2 fragments for most tissues and at
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INTRODUCTION
For the successful use of monoclonal antibodies
(moAbs) in radioimmunoscintigraphy (RIS) and/
or radioimmunotherapy (RIT), it is important that
the antibody has optimal antigen-binding capac-
ities, optimal penetration into tumor tissue, and
rapid clearance from normal tissues. This should
lead to high and specific tumor targeting.1 The
first radiolabeled moAb preparations used to vi-
sualize or treat malignancies consisted of whole
IgG. Later, F(ab9)2 and Fab or Fab9 fragments
were tested for the same applications. Intact IgG
is composed of four polypeptide chains, two
heavy and two light chains, linked by disulfide
bonds. Enzymatic degradation of the intact IgG
with pepsin results in the formation of F(ab9)2
fragments that can be reduced to Fab9 fragments,
while enzymatic degradation of IgG with papain
results in the formation of Fab fragments. F(ab9)2
fragments still contain two antigen binding sites
(bivalent), while Fab and Fab9 fragments are
monovalent, resulting in a reduced affinity for the
target cell.
In experimental studies, there have been con-
tradictory reports with respect to the optimal an-
tibody form for RIT. Compared to fragments, in-
tact IgG has a much longer residence time in the
blood (IgG . F(ab9)2 . Fab).1—4 Because high
and sustained blood levels of the antibody are the
driving force for tumor uptake, intact IgG has a
higher uptake (%ID/g) in the tumor. For the same
reason, however, whole IgG delivers a higher ra-
diation-absorbed dose to the bone marrow, the
dose-limiting organ in RIT.2,4 Advantages of the
fragments over intact IgG are rapid clearance
from the blood and normal tissues, generally re-
sulting in higher tumor-to-normal tissue ratios,
and a reduced radiation-absorbed dose to bone
marrow.5 In addition, tumor penetration may be
better for the smaller antibody fragments, lead-
ing to a more homogeneous intratumoral distri-
bution.3 Furthermore, the antibody fragments are
believed to be less immunogenic as a result of
their reduced residence time in the blood.6,7 On
the other hand, the antibody fragments may show
increased renal uptake resulting from reabsorp-
tion by the renal tubular cells. This, in turn, may
lead to radiation-induced nephrotoxicity, if a ra-
diometal is used instead of radioiodine.8
In several preclinical reports, F(ab9)2 fragments
were favored for RIT, arguing that the reduced
absolute uptake in the tumor can be compensated
by the increased total amount of radioactivity that
can be administered.2,9 In contrast, better antitu-
mor efficacy of intact IgG because of a higher ra-
diation-absorbed dose delivered to the tumor by
whole IgG has been observed.4 The hypothesis
that monovalent antibody fragments, with their
reduced antibody affinity, are less suitable for
RIT purposes than the bivalent antibodies has
also been questioned.2,3 In mice, in a direct com-
parison, monovalent Fab fragments outperformed
intact IgG regarding antitumor efficacy, presum-
ably because of their homogeneous and rapid up-
take and high maximum tolerated activities, re-
sulting in higher dose rates.3
In the majority of RIT studies in humans, in-
tact IgG has been used.10,11 In a few clinical 
studies, whole IgG was compared to a fragment
form, but it remains unclear which antibody form
is most suited for RIT.1,12,13 The conclusions
from various studies range from reaching the
same percentage of injected dose per gram
(%ID/g) in metastases13 to a substantial advan-
tage for F(ab9)2 fragments, compared to intact
IgG in RIT.12 In a direct comparison between in-
tact cMOv18-IgG and its F(ab9)2 fragments in
ovarian cancer patients, the tumor-to-normal tis-
sue ratios for both antibody forms were similar,
suggesting a similar performance for therapeutic
application.1 It appears that the most optimal an-
tibody form has to be defined specifically for
each antibody-antigen system.
In our previous studies, the IgG form of moAb
cG250 was used.14—17 MoAb cG250 is directed
against the G250/MN CA IX antigen on RCC
cells.18,19 Almost all (.95%) clear-cell RCCs ex-
press the G250 antigen on the cell surface.20 Ap-
proximately 75% of RCCs are of the clear-cell
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most time points, although absolute uptake in all tissues was considerably lower for the F(ab9)2 frag-
ments. In patients with primary RCC, tumorous kidney tissue was faintly visualized with 131I-cG250-
F(ab9)2 fragments. The intact IgG form of cG250 appears to be more suitable than cG250-F(ab9)2 frag-
ments for targeting clear-cell RCC.
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type.21 For cG250 RIT in RCC patients, the most
optimal antibody form has not yet been estab-
lished.
To directly compare cG250-F(ab9)2 fragments
to cG250-IgG, we performed a dual-label, dual-
isotope biodistribution study in mice bearing sub-
cutaneous (s.c.) RCC xenografts. Furthermore,
we carried out a pilot study in RCC-bearing pa-
tients to determine the pharmacokinetics and ki-
netics of tumor targeting of 131I-labeled cG250-
F(ab9)2 fragments to address the maximal uptake
(%ID) of F(ab9)2 fragments in a tumoros kidney.
MATERIALS AND METHODS
F(ab9)2 Fragments of Monoclonal Antibody
cG250
F(ab9)2 fragments of chimeric moAb G250 were
produced from clinical-grade cG250 (Centocor
Europe BV, Leiden, The Netherlands). Briefly,
0.25 g of cG250 (5 mg/mL) was digested with 5
mg of pepsin in 0.1 M of citrate buffer, at a pH
of 3.8. After 4 hours at 37¡C, the digestion was
stopped by adding 10 mL 1.0 M Tris. Subse-
quently, the cG250 F(ab9)2 material was purified
on a cation exchange column (MONO-S 16/10,
Amersham Pharmacia Biotech, Uppsala, Swe-
den) eluted with 40 mM of acetate buffer, at a
pH of 5.2, with a 0 R 400 mM LiCl gradient.
The F(ab9)2 containing fractions were buffer-
changed by ultrafiltration, and the F(ab9)2 frag-
ments were vialed aseptically in 20-mL vials (5.0
mg/mL, 1.2 mL/vial). The cG250-F(ab9)2 frag-
ments met the following release criteria:
(1) sterility: no microbial contamination
(2) endotoxin: ,40 pg/mL, and
(3) protein composition: 85% F(ab9)2 fragments,
,1% IgG and ,1% Fab9 fragments, and
pepsin below the detection limit (,0.2%),
using the quantitative analysis of SDS-poly-
acrylamide gelelectrophoresis (SDS-PAGE).
The immunoreactive fraction of the radioiodi-
nated cG250 F(ab9)2 preparation was .95% im-
mediately postlabeling and .90% after 4 hours
of incubation in serum, essentially as described
by Lindmo et al., with minor modifications.14,22,23
Scatchard analysis revealed that the affinity of
125I-cG250 F(ab9)2 was 2.6 3 109 M21, while the
affinity of parental 125I-cG250-IgG1 was 2.3 3
109 M21 in the same, simultaneously run assay.
Radiolabeling and Quality Control
For the biodistribution experiments, intact IgG-
cG250 was radiolabeled with 131I and cG250-
F(ab9)2 fragments, with 125I as described previ-
ously (specific activity: 2 mCi/mg).24 For clinical
use, the cG250-F(ab9)2 fragments were radioiod-
inated with 131I (MDS Nordion, Fleurus, Bel-
gium), according to the IodoGen method using a
remote system, as described previously (specific
activity: 30 MBq/mg).14,15,25 The radiochemical
purity of radiolabeled cG250-F(ab9)2 fragments
was determined by instant thin-layer chromatog-
raphy (ITLC) using ITLC silica gel strips (Gel-
man Sciences, Inc., Ann Arbor, MI) using 0.15
M of citrate buffer, at a pH of 5.0, as the mobile
phase (release criterion: ,5% free radioiodine).
Also, prior to each administration of cG250-
F(ab9)2 fragments, the immunoreactive fraction
at infinite antigen excess was determined on
freshly trypsinized SK-RC-52 RCC cells, as de-
scribed by Lindmo et al.22
The stability of the cG250 F(ab9)2 fragments
in the circulation was investigated by incubating
radioiodinated cG250 F(ab9)2 in serum at 37¡C
(106 cpm/mL). Samples were drawn at 1, 2, 3, 4,
and 24 hours after incubation and analyzed on
SDS-PAGE.
Biodistribution Experiments in Mice
The in vivo characteristics of the radioiodinated
cG250 F(ab9)2 preparation were determined in
nude mice with s.c. SK-RC-52 human renal cell
carcinoma xenografts and compared to the per-
formance of radioiodinated intact IgG cG250.23
SK-RC-52 cells were cultured in RPMI medium
(Life Technologies, Breda, The Netherlands) and
supplemented with 10% fetal calf serum (FCS)
at 37¡C in a humidified atmosphere with 5% CO2.
Cells were washed in saline, trypsinized, washed
in RPMI 1 10% FCS, and 2 3 106 cells (volume
0.2 mL) were injected subcutaneously (s.c.) into
the right flank of 6—8-week-old BALB/c nu/nu
mice. The biodistribution experiments were ini-
tiated 2 weeks after the inoculation of the tumor
cells. RCC tumor-bearing mice were randomly
divided into 5 groups of 5 mice. Mice were in-
travenously (i.v.) coinjected with 10 mCi 131I-
cG250-IgG and 10 mCi 125I-cG250-F(ab9)2.
Mean tumor weight was 0.039 g, with a range of
0.012—0.080 g, and all mice received a protein
dose of 5 mg intact IgG and 5 mg F(ab9)2-cG250
(total injection volume 200 mL/mouse). Groups
of mice were killed at 1, 2, 3, 5, and 7 days postin-
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jection (p.i.), and the biodistribution of both ra-
diolabels was determined. The tumor and normal
tissues (blood, muscle, lung, spleen, kidney, liver,
and small intestines) were dissected, weighed,
and counted in a gamma counter (1480 Wizard
3", PerkinElmer Life Sciences, Boston, MA). To
correct for radioactive decay, injection standards
were counted simultaneously. The activity in
samples was expressed as the percentage of in-
jected dose per gram of tissue (%ID/g). All ani-
mal experiments were approved by the Animal
Experiments Committee of the University Med-
ical Center Nijmegen and were performed in ac-
cordance with their guidelines.
Patient Characteristics
Five (5) patients, ages between 41 and 76, with
clinical diagnoses of primary renal cell carcinoma
were included (Table 1). Patients had to have a
Karnofsky performance status .70%, and had to
be over 18 years of age. Furthermore, they were
excluded when they were pregnant or lactating,
or had been previously injected with any type of
monoclonal antibody of murine origin. Also, they
could not participate in the case of untreated hy-
percalcemia, liver, and/or renal failure, central
nervous system dysfunction, severe ischemic
myocardial disease, or known arrhythmia. The
study was approved by the Medical Ethical Com-
mittee of the University Medical Center Nij-
megen. Prior to study entry, written, informed
consent was obtained from all patients.
Clinical Study Design and
Radioimmunoscintigraphy
Within 30 days before study entry, a baseline
computed tomography (CT) scan of the abdomen
of each patient was obtained for adequate mea-
surement of the primary tumor. Prior to the ad-
ministration of the 131I-cG250-F(ab9)2 fragments,
the medical history was taken, a physical exam-
ination was performed, and baseline blood sam-
ples were drawn for routine blood chemistry,
hematology, and thyroid function.
To prevent 131I uptake in the thyroid, patients
received 100 mg of potassium iodide twice-daily
and 200 mg of potassium perchlorate 4 times
daily, starting on the day of the F(ab9)2 adminis-
tration. This regimen was continued for 1 week.
Patients received a diagnostic i.v. infusion of
5 mg cG250-F(ab9)2 fragments labeled with 150
MBq 131I (total volume 10 mL), followed by the
acquisition of 6 whole-body scans at 5 minutes,
3 hours, 1, 2, 3, and 4 days p.i. Simultaneously,
aliquots of dose were scanned to allow for a quan-
titative analysis of the images. The images were
recorded using a double-headed gamma camera
(Multispect 2, Siemens Inc., Hoffman Estates,
IL), equipped with parallel-hole, high-energy col-
limators (symmetric 15% window over 364 keV,
scan speed 10 cm/min [5 minutes and 3 hours, 1
and 2 days p.i.]) and 5 cm/minutes [3 and 4 days
p.i.]) and stored digitally in a 256 3 1024 matrix.
At the same time points, except for the last 2 days,
planar images of the upper abdomen were recorded
with a preset count number of 1,000,000 counts.
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Table 1. Patient Characteristics, Size, and Location of Primary Tumor, Pathology, and Immunohistochemical G250 Staining
Maximum size
Age (height 3 width 3 length [cm])
Patient at study and location of Pathology, tumor (T) Immunohistochemical
no. entry Gender primary kidney tumor Nephrectomy classification of UICC G250 staining
1 63 M 7 3 7 3 8, right Yes Clear cell RCC, pT3b 111b
2 41 M 6 3 7 3 8, left Yes Clear cell RCC, pT3a n.d.c
3 60 M 4.5 3 4.5 3 4.5, right Yes Clear cell RCC, pT1 111
4 71 M 15 3 12 3 17, right No Clear cell RCC, pTxa n.d.d
5 76 M 6 3 5 3 5, right Yes Clear cell RCC, pT3b 111
UICC, International Union Against Cancer; n.d., not determined.
aThe size of the primary RCC could not be established, as the lesions were irresectable. The pathological diagnosis of clear
cell RCC was established from a metastatic lesion from the omentum.
bMore than 95% of cells stained positive for G250.
cNo representative frozen tissue available (only necrotic tissue).
dNo frozen tissue available.
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Pulse rate, blood pressure, and temperature
were checked once every hour up to 4 hours p.i.,
and, thereafter, once-daily until the last scanning
day. At 4 days p.i., the chemistry and hema-
tological parameters were checked again. Ap-
proximately 3 months later, blood was sampled
to reevaluate thyroid function. Once a nephrec-
tomy had been performed, the clinical diagnosis
was confirmed by routine pathology of the kid-
ney tumors, and the stage was determined using
the international union against cancer (UICC)
Tumor-Node-Metastases (TNM) and Heidelberg
classification systems.21,26
Pharmacokinetics and Quantitative Analysis
of the Scintigraphic Images
To determine the pharmacokinetics of 131I-
cG250-F(ab9)2 fragments in the blood of patients,
blood samples were drawn at 5 minutes and 0.5,
1, 2, 4, 8, and 12 hours p.i., and at 1, 2, 3, and 4
days p.i. The samples were counted in a well-type
gamma counter (1480 Wizard 3", PerkinElmer
Life Sciences, Boston, MA). To correct for ra-
dioactive decay, injection standards were counted
simultaneously. The activity in these samples was
expressed as the percentage of injected dose per
gram (%ID/g). The half-life of the disappearance
from plasma (t 1/2) was calculated by nonlinear,
least-square regression analysis (a and b phase).
Serial whole-body images were used to quan-
titate the uptake of 131I-cG250-F(ab9)2 fragments
in the whole body, heart, liver, kidney, primary
kidney tumor, and the nonaffected kidney, as has
been described previously.27—29 Briefly, regions
of interest (ROIs) were drawn on the anterior and
posterior whole-body images.29 Absolute activ-
ity in tumors and organs was calculated, using
the conjugated-view method with partial back-
ground subtraction, according to Buijs et al.27,28
Subsequently, the activity in tissues was cor-
rected for physical decay and attenuation, and 
expressed as %ID, setting the number of counts
in the whole-body image recorded immediately
after injection at 100%. Uptake in normal kidney
and primary kidney tumors was also expressed as
%ID/g, assuming that 1 mL of tissue equals 1 g.
The volume of the kidney tumor was derived
from CT measurements, using the formula
p(length 3 width 3 height)/6. The weight of a
normal kidney was derived from a standard adult
male phantom and was assumed to be 150 g.
Immunohistochemistry
Immunohistochemistry on frozen tissues was
carried out, as described previously.14 Briefly, 4-
mm cryostat sections were acetone-fixed, dried,
and washed. Sections were incubated with 100
mL of 10 mg/mL murine antibody G250 for 1
hour at room temperature and washed. Subse-
quently, sections were incubated with rabbit an-
timouse IgG conjugated to horseradish perox-
idase (RAMPO, DAKO, Carpentina, CA),
washed, and developed with 3-39-diaminobenzi-
dine/0.03% hydrogen peroxide.
Statistical Analysis
Statistical analysis was performed using the un-
paired StudentÕs t test. Differences were consid-
ered significant when p , 0.05, and two-sided.
All values are expressed as mean 6 standard de-
viation (SD), unless stated otherwise.
RESULTS
Radiolabeling and Quality Control
The labeling efficiency of the radioiodination of
the clinical-grade F(ab9)2 fragments was always
between 85% and 90%. After purification, more
than 98% of the 131I-activity in the antibody
preparation was protein-bound, as determined by
ITLC. The immunoreactive fraction of 131I-
cG250-F(ab9)2 ranged between 88% and 94%
(mean: 90%).
The autoradiogram of the gel showed that the
F(ab9)2 fragments were stable in serum during at
least 24 hours and that no monovalent Fab9-frag-
ments were formed (Fig. 1).
Biodistribution Experiments in Mice
The results of the biodistribution experiments are
shown in Figure 2. In all tissues analyzed, the up-
take of 125I-cG250-F(ab9)2 fragments was signif-
icantly lower when compared to the uptake of 
intact 131I-cG250-IgG (p between , 0.0001
and , 0.05) (Fig. 2A). Maximum tumor uptake
of cG250-F(ab9)2 fragments was already reached
at 1 day p.i., whereas the maximum uptake of in-
tact radiolabeled cG250 was reached 3 days p.i.
(Fig. 2A). Tumor-to-blood ratios were only sig-
nificantly different at 1 and 2 days p.i., with the
highest ratio for the125I-cG250-F(ab9)2 fragments
(2.7 6 0.6) at 1 day p.i. (Fig. 2B). There was no
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difference in maximum tumor-to-blood ratio
reached at 7 days p.i. (approximately 3 for both
preparations) (Fig. 2B). Most of the tissue-to-
blood ratios in the other tissues were similar for
the F(ab9)2 fragments and intact IgG, although a
few significant differences were noted, e.g., kid-
ney-to-blood and liver-to-blood at 1, 2, and 5
days p.i. (Fig. 2B).
To estimate the radiation dose that could be
guided to the tumor with 131I-labeled F(ab9)2 and
IgG, for both antibody forms the area under the
curve (AUC) was calculated for the tumor and
the blood. For intact IgG, the AUCtumor 5 26.6
and AUCblood 5 18.6, while for F(ab9)2 the
AUCtumor 5 4 and AUCblood 5 2.1, suggesting
that, in this mouse model, a higher radiation dose
(1.4-fold) can be guided to the tumor with 131I-
cG250 F(ab9)2, compared to 131I-cG250 IgG. In
these estimations, the effects of the different dose
rates are not accounted for.
Clinical Observations and
Radioimmunoscintigraphy
All 131I-cG250-F(ab9)2 fragment injections were
well tolerated by the patients. No significant
changes in vital signs, hematological or blood
chemistry parameters, or thyroid function were
observed (2 patients were lost to follow-up for
thyroid evaluation). After the 5-day protocol had
been completed, all patients underwent surgery
(Table 1). In 4 patients, a nephrectomy was per-
formed; in 1 patient (patient 4), the tumor turned
out to be irresectable during surgery and was em-
bolized. The findings of routine pathology of the
kidney tumors that were removed are docu-
mented in Table 1. In 3 of 4 tumor tissues ob-
tained after nephrectomy, immunochemistry
showed that 95% of the RCC cells stained posi-
tive for G250. One (1) frozen tissue sample (pa-
tient 4) consisted mainly of necrotic tissue, and,
therefore, the G250 expression of the frozen sam-
ple could not be reliably assessed (Table 1).
In 2 patients (3 and 4), faint tumor targeting
was observed from 48 hours p.i. onwards (Fig.
3). Significant targeting of 131I-cG250-F(ab9)2
fragments to the primary RCC tumors was ob-
served in none of the patients during the time 
period in which gamma-camera scans were re-
corded. Immediately after injection, the primary
tumor appeared as photopenic areas in posterior
scintigraphies in the majority of patients (1—4)
(Fig. 4).
Pharmacokinetics and Quantitative Analysis
of the Scintigraphic Images
Clearance of the radiolabel from the blood after
an i.v. injection of radioiodinated cG250-F(ab9)2
fragments was characterized by a rapid distribu-
tion phase, with a half-life (t 1/2 a) ranging from
4.1 to 6.3 hours (mean: 4.8 hours), and a slower
elimination phase, with a half-life (t 1/2 b) rang-
ing from 25.8 to 34.1 hours (mean: 29.0 hours).
The total 131I activity in the body of 5 RCC pa-
tients during the first 4 days after 131I-cG250-
F(ab9)2 administration is shown in Figure 5A. For
comparison, historical data showing the activity
in whole body and relevant organs at 96 hours
after injection of intact 131I-labeled cG250-IgG is
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Figure 1. Autoradiogram of the SDS-acrylamide gel, with the samples of 125I-cG250 F(ab9)2 fragments incubated in serum at
37¡C during 0—24 hours. In the first lane, a sample of the 125I-cG250 F(ab9)2 preparation was run as a reference.
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Figure 2. Biodistribution of 125I-cG250 F(ab9)2 and 131I-cG250-IgG in nude mice with s.c. SK-RC-52 human renal cell carci-
noma xenografts. Groups of 5 mice were killed at 1, 2, 3, 5 and 7 days p.i. Uptake (%ID/g) (A) and tissue-to-blood ratios (B) in
various tissues. s.e.m., standard error of the mean.
A
B
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Figure 3. Posterior whole-body images of patient 3 after an i.v. injection of 131I-cG250-F(ab9)2 fragments at: 5 minutes (A); 3
hours (B); and 1 (C), 2 (D), 3 (E), and 4 days p.i. (F). At later time points, a faint uptake was noticed in the region of the pri-
mary RCC tumor in the upper pole of the right kidney (arrow in F).
A B C
D E F
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also depicted.29 F(ab9)2 fragments cleared signif-
icantly faster from the body compared to intact
IgG; at 96 h p.i., only 20 %ID of the F(ab9)2 frag-
ments was still present in the body versus ap-
proximately 60 %ID for intact cG250 (Fig. 5A).
The same pattern was observed for the activity in
relevant organs (Fig. 5B). The activity in the heart
after an injection of 131I-cG250-F(ab9)2 frag-
ments decreased with time, whereas the activity
in the other organs reached a maximum uptake at
3 hours p.i. Thereafter, the activity decreased (Fig.
5B). The mean activity (%ID/g) in the primary
RCC was never higher than the mean activity
(%ID/g) in the normal contralateral kidney (Fig.
5C). Thus, specific accumulation of radioiodinated
F(ab9)2 fragments in primary RCCs could be quan-
titatively demonstrated in zero of 5 patients.
DISCUSSION
This pilot study describes the results of the ap-
plication of 131I-labeled cG250-F(ab9)2 fragments
in mice and patients. In mice, our results with
chimeric moAb G250 were in line with previous
studies by Van Dijk et al., who compared murine
G250-F(ab9)2 fragments to murine G250-IgG in
the same SK-RC-52 tumor model.30 In mice, the
accumulation of 131I-cG250-F(ab9)2 fragments in
tumor and normal tissues was considerably lower
and clearance of the radiolabel from all tissues
was faster, compared to radioiodinated intact
cG250-IgG. Nevertheless, the tumor-to-blood ra-
tios at the first time points analyzed were higer
for the F(ab9)2 fragments, indicating a potential
advantage of F(ab9)2 in RIS and RIT. From 3 days
p.i. onwards, tumor-to-blood ratios were similar
for F(ab9)2 and IgG. Despite similar biokinetics,
the use of bivalent fragments might be advanta-
geous because of improved tumor penetration and
reduced immunogenicity.
In patients, i.v. injection of radioiodinated
cG250-F(ab9)2 fragments did not result in the
clear visualization of primary RCC tumors. The
tumor was faintly visualized in only 2 patients
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Figure 4. Posterior images of the abdomen of patient 2 after an i.v. injection of 131I-cG250-F(ab9)2 fragments at: 5 minutes
(A); 3 hours (B); and 1 (C) and 2 days p.i. (D). The primary kidney tumor was situated at the lower pole of the left kidney (circle).
A B
C D
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from 2 days p.i. onwards. Because of the poor lo-
calization of the tumor, specific targeting of the
131I-cG250-F(ab9)2 fragments in the tumor could
not be quantitatively demonstrated. Relatively
high uptake in normal kidney was observed for
the F(ab9)2 fragments, most likely the result of
reabsorption of F(ab9)2 fragments by the renal
tubular cells. These results are in contrast with
previous observations after the injection of intact
131I-cG250 in RCC patients with in situ primary
tumors.14 In the latter study, excellent visualiza-
tion of G250 antigen-positive tumors was ob-
tained, usually from 1 day p.i. onwards. Because
of the clearance of the radiolabeled moAbÑlow-
ering background levelsÑimage quality im-
proved with time, up to 7 days p.i..14 Further-
more, there was no physiologic uptake in the
normal kidney at 4 days p.i. with intact 131I-
cG250.16
The limited accretion of the F(ab9)2 fragments
in RCC tumors could be the result of the insta-
bility of the F(ab9)2 fragments in vivo. However,
this was ruled out by checking the immunoreac-
tivity and by analyzing the 131I-cG250 F(ab9)2
preparation on SDS-PAGE before and after in-
cubation in the blood. These data demonstrated
that the immunoreactivity of the preparation was
preserved and that the radiolabel in the blood re-
mained associated with F(ab9)2 fragments, and
there was no indication of formation of labeled
degradation products (e.g., monovalent Fab9).
Furthermore, the clinical pharmacokinetic data
do not support the degradation of the F(ab9)2
preparation in the circulation. The clearance of
the radiolabel from the blood is in line with clear-
ance rates observed for F(ab9)2 fragments in other
studies.1,31 The t 1/2 b of Fab9 fragments is re-
ported to be considerably shorter (t 1/2 , 20 h).32
It could also be the result of G250 antigen-neg-
ative kidney tumors. This explanation was ruled
out by the results of routine pathology (all tumors
were clear-cell RCCs) and the immunohisto-
chemistry data (in 3 of 4 tissues, .95% of the
tumor cells stained positive for G250). One (1)
tissue sample consisted mainly of necrotic tumor
tissue, and, therefore, immunohistochemistry
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Figure 5. Total activity (%ID) in whole
body (A), relevant organs (B), and activ-
ity concentration (%ID/g) (C) in the pri-
mary kidney tumor and contralateral nor-
mal kidney at 5 minutes; 3 hours; and 1,
2, 3, and 4 days after i.v. injection of 148
MBq 131I-cG250-F(ab9)2 fragments in pa-
tients (n 5 5). For comparison, activity
(%ID) in whole body and relevant organs
at 4 days after i.v. injection of intact 131I-
cG250 in patients is also given in A and
B.14,29
A
B
C
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could not be performed. Even though large,
necrotic tumors might have hampered tumor tar-
geting and visualization with 131I-cG250-F(ab9)2,
the presence of necrotic tissue did not previously
hamper uptake of intact 131I-cG250 in the tumor
and visualization of the tumor.14
One might postulate that the protein dose of
F(ab9)2 fragments was suboptimal. The protein
dose of the F(ab9)2 fragments (5 mg) was derived
from the optimal protein dose (5—10 mg) for in-
tact 131I-cG250.14 Average tumor uptake of
cG250-IgG in the tumor was approximately 0.01
%ID/g.14 With cG250-IgG, antigen saturation
was observed only at protein doses exceeding 10
mg of intact cG250.14 Thus, 5-mg radioiodinated
cG250-F(ab9)2 fragments likely did not saturate
the tumors. Conversely, at relatively low protein
doses of 2 mg cG250-IgG, enhanced uptake in
the liver was observed, which was saturable and,
presumably, the result of the known G250 anti-
gen expression on the larger bile ducts.14 In the
present study, uptake in liver immediately postin-
jection of 131I-cG250 F(ab9)2 fragments was ap-
proximately 10%ID, which is in the same range
as the observed hepatic uptake of approximately
12%ID immediately after the injection of 131I-
cG250-IgG.29 Thus, underdosing of the F(ab9)2
fragments is also an unlikely explanation.
Lastly, there might be a concern of the appro-
priatness of the radiolabel used. Although we re-
cently showed that, with a residualizing radionu-
clide such as 111In, more metastatic RCC lesions
could be visualized, and a higher uptake of 111In-
radiolabeled cG250 could be achieved in these
metastases, compared to 131I-cG250, the reported
high uptake in primary RCCs (up to 0.52%ID/g)
with 131I-cG250 by Steffens et al., demonstrated
that radioiodinated G250 can visualize RCC le-
sions very well.14,29
Thus, based on the observations reported in our
current study, it is concluded that the intact IgG
form of moAb cG250 that has been used, up to
now, is currently the most appropriate antibody
form for RIS and RIT in patients with RCC.
CONCLUSION
In conclusion, the tissue-to-blood ratios in mice
were similar for intact IgG and the 131I-cG250-
F(ab9)2 fragments for most tissues and at most
time points, although absolute uptake in all tis-
sues was considerably lower for the F(ab9)2 frag-
ments. In patients with their primary RCC tumor
in situ, scintigraphic detection and tumor target-
ing of tumorous kidney tissue was inadequate
with 131I-cG250-F(ab9)2 fragments. These results
differ from the findings in a previous patient
study with the 131I-labeled intact IgG moAb
cG250, in which clear tumor targeting was ob-
served from 1 day p.i. onwards. Apparently, sus-
tained high blood levels of intact cG250-IgG are
a prerequisite for the effective accumulation of
the antibody in RCC tumor tissue. Thus, the in-
tact IgG form of moAb cG250 that has been used
up to now is more suitable than cG250-F(ab9)2
fragments for targeting RCC tumors.
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